Ozmosi | DUK-CPG-001 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

DUK-CPG-001

Alternative Names: duk-cpg-001, dukcpg001, duk cpg 001
Clinical Status: Inactive
Latest Update: 2024-02-20
Latest Update Note: Clinical Trial Update

Product Description

TLR9 Agonist for Myeloid Malignancies and Lymphoid Malignancies (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02452697)

Mechanisms of Action: TLR9 Agonist

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cristina Gasparetto
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Lymphoma, Non-Hodgkin|Pregnancy Outcomes|Bone Marrow Transplantation|Hematopoietic Stem Cell Transplant|Allogeneic Stem Cell Transplant|Liver Transplant|Nut Hypersensitivity|Animal Hypersensitivity|Graft vs Host Disease|Environmental Hypersensitivity

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT02452697

NK-DCI

P2

Unknown status

Allogeneic Stem Cell Transplant|Environmental Hypersensitivity|Hematopoietic Stem Cell Transplant|Pregnancy Outcomes|Nut Hypersensitivity|Liver Transplant|Animal Hypersensitivity|Graft vs Host Disease|Bone Marrow Transplantation

2022-07-23

50%

2026-02-03

NCT02115126

Pro00042574

P2

Withdrawn

Lymphoma, Non-Hodgkin

2020-01-01

2019-03-20

Treatments

Recent News Events

Date

Type

Title